Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Super-Sharp brain scanner could revolutionize diagnosis of dementia and cancer

NCT ID NCT07595666

Diagnosis Sponsor: prof. dr. Koen Van Laere Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new ultra-high resolution PET/CT scanner, the NeuroEXPLORER, with standard clinical PET/CT scanners for imaging the head and neck. Researchers aim to see if the new device provides more detailed images to improve diagnosis of conditions like dementia, Parkinson's disease, brain tumors, and head and neck cancers. About 1,600 participants will receive both scans in one visit, and their images will be compared for accuracy and diagnostic confidence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this scanner could provide clearer, more detailed images to help doctors diagnose and monitor brain and neck conditions more accurately.
What could go wrong
This is an early-stage device comparison study, not a treatment trial. The new scanner may not prove significantly better in practice, and its benefits may be limited to certain conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

28 days and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All subjects referred for standard-of-care PET in the indications for the substudies are eligible. Exclusion Criteria: * Subject is unwilling to avoid unusual, unaccustomed, or strenuous physical activity beginning 4 days prior to tracer injection up to 1 day after tracer injection. * Subject does not understand the study procedures. * Subject is unwilling or unable to perform all of the study procedures or is considered unsuitable in any way by the principal investigator. * Subject has had exposure to ionizing radiation (\> 1 mSv) in other research studies within the last 12 months. * Subject does not agree that incidental findings are communicated to the general practitioner and to the participant him/herself. * Incapacitated patients that cannot give consent by themselves (in particular for substudies 1-3 in neurodegeneration).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS (amyotrophic lateral sclerosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease amyotrophic lateral sclerosis brain cancer dementia epilepsy frontotemporal dementia head and neck cancer Head and Neck Neoplasms Lewy body dementia Lewy Body Disease movement disorder neuroblastoma parathyroid gland adenoma Parathyroid Neoplasms Parkinson disease pituitary gland adenoma Pituitary Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS (amyotrophic lateral sclerosis) Alzheimer's disease Brain tumors Dementia Epilepsy Fronto-temporal dementia Head and neck tumors Large vessel vasculitis Lewy body dementia Movement disorders Neuroblastoma Parathyroid adenomas Parkinson disease (disorder) Pituitary adenoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UZ Leuven

    Leuven, Vlaams-Brabant, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.